<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00690404</url>
  </required_header>
  <id_info>
    <org_study_id>D0475C00005</org_study_id>
    <nct_id>NCT00690404</nct_id>
  </id_info>
  <brief_title>AZD 2066 Single Dose Formulation and Food Effect Study in Healthy Volunteers</brief_title>
  <official_title>A Phase 1, Single-center, Randomized, Open-label, Two-way Crossover, Formulation and Food Effect Study in Healthy Volunteers, to Assess the Pharmacokinetics of AZD 2066 After Single Doses of a New Oral Solid Formulation and an Oral Solution</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A open label two way crossover formulation and food effect study in healthy volunteers to
      assess the pharmacokinetics of a single dose of AZD2066 new oral solid formulation and an
      oral solution
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AZ2066 pharmacokinetics</measure>
    <time_frame>several samples within 72 hrs</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of food on AZD2066 pharmacokinetics</measure>
    <time_frame>several samples over 72 hrs</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD2066</intervention_name>
    <description>single oral dose</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical normal physical findings, including BP, pulse rate &gt;45 bpm, ECG and
             laboratory assessments

          -  Body Mass Index (BMI) of ≥18 to ≤30 kg/m2 and weight of ≥50 to ≤100 kg

        Exclusion Criteria:

          -  History of hypersensitivity, allergy or atopic/skin disease as judged by Investigator.

          -  History of somatic or psychiatric disease/condition, which may interfere with the
             objectives of the study as judged by the Investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eleanor Lisbon, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quintiles, Inc. Overland Park, Kansas, USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Heather Wray, MB, ChB, FFPM</last_name>
    <role>Study Chair</role>
    <affiliation>AstraZeneca Charnwood England</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ivan Eggens, MD</last_name>
    <role>Study Chair</role>
    <affiliation>AstraZeneca , Södertälje, Sweden</affiliation>
  </overall_official>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 2, 2008</study_first_submitted>
  <study_first_submitted_qc>June 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2008</study_first_posted>
  <last_update_submitted>December 8, 2010</last_update_submitted>
  <last_update_submitted_qc>December 8, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 10, 2010</last_update_posted>
  <responsible_party>
    <name_title>Rolf Karlsten, M.D., Medical Science Director, Emerging Neuroscience</name_title>
    <organization>AstraZeneca Pharmaceuticals</organization>
  </responsible_party>
  <keyword>formulation</keyword>
  <keyword>pharmacokinetic</keyword>
  <keyword>crossover formulation</keyword>
  <keyword>food effect</keyword>
  <keyword>oral solution</keyword>
  <keyword>healthy volunteers</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

